Anifrolumab
Sign in to saveAlso known as MDX-1333, MEDI-546
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
~2 min read
Encyclopedic overview
9 sectionsContents
- Mechanism of Action
- Adverse effects
- History
- Society and culture
- Legal status
- Names
- References
- Further reading
- External links
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Anifrolumab was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The U.S. Food and Drug Administration considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “Anifrolumab” article, available under the CC BY-SA 4.0 licence.